title: Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?
authors.affiliation: Abteilung für pädiatrische Hämatologie & Onkologie, Universitätskinderklinik Hamburg, Germany.
authors.forename: S S
authors.initials: SS
authors.lastname: Bielack
authors.forename: R
authors.initials: R
authors.lastname: Erttmann
authors.forename: B
authors.initials: B
authors.lastname: Kempf-Bielack
authors.forename: K
authors.initials: K
authors.lastname: Winkler
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin